Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-agent azacitidine for pre-treated AML patients not eligible for further intensive re-induction chemotherapy
KCT0004569Phase 2Not yet recruiting
- Sponsor
- Boryung
- Start
- Feb 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of azacitidine in acute myeloid leukemia (AML), sponsored by Boryung. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on KCT0004569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004569.